US8372873B2ExpiredUtilityPatentIndex 52
Inhibitors of serine proteases
Est. expiryAug 26, 2025(expired)· nominal 20-yr term from priority
A61P 37/02A61P 43/00A61P 31/12A61P 31/14A61P 1/16C07D 498/10A61K 31/24C07K 5/06034
52
PatentIndex Score
1
Cited by
363
References
23
Claims
Abstract
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
Claims
exact text as granted — not AI-modified1. A method of inhibiting a serine protease in a cell, comprising contacting the cell with a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
each A is —CH 2 —;
each B is —CH 2 —;
each R 1 is
wherein:
U is a bond or —O—;
V is an alkyl;
T is —C(O)—; and
R is an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, heteroaryl, alkoxy, or cycloalkoxy, and is optionally substituted with 1 to 3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, aliphatic, haloaliphatic, (aliphatic)oxy, (halo(aliphatic))oxy, (aliphatic(oxy(aryl)))oxy, aryl, heteroaryl, haloaryl, cycloaliphatic, or heterocycloaliphatic;
each R 2 is —Z B R 5 , wherein each Z B is independently a bond or an optionally substituted aliphatic wherein up to four carbon units of Z B are optionally and independently replaced by —C(O)—, —C(S)—, —C(O)NR B —, —C(O)NR B NR B —, —C(O)O—, —C(O)C(O)—NR B —, —NR B C(O)O—, —NR B C(O)NR B —, —NR B NR B —, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, or —NR B SO 2 NR B —, provided that —SO—, —SO 2 —, or —SO 2 NR B — is not directly bound to the carbonyl in formula (I);
each R 5 is independently R B , halo, —OH, —CN, —NO 2 , —NH 2 , alkoxy, or haloalkoxy;
each R B is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
or, R 1 and R 2 , together with the atoms to which they are attached, form an optionally substituted heterocycloaliphatic ring;
each R 3 is an optionally substituted aliphatic, amino, sulfonyl, sulfanyl, sulfinyl, sulfonamide, sulfamide, sun, —O—R 3A , an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
each R 3A is independently an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl; and
each of Y and Y′ is H.
2. The method according to claim 1 , wherein said serine protease is an HCV NS3 protease.
3. A method of treating an HCV-infected patient, comprising administering to said patient a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
each A is —CH 2 —;
each B is —CH 2 —;
each R 1 is
wherein:
U is a bond or —O—;
V is an alkyl;
T is —C(O)—; and
R is an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, heteroaryl, alkoxy, or cycloalkoxy, and is optionally substituted with 1 to 3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, aliphatic, haloaliphatic, (aliphatic)oxy, (halo(aliphatic))oxy, (aliphatic(oxy(aryl)))oxy, aryl, heteroaryl, haloaryl, cycloaliphatic, or heterocycloaliphatic;
each R 2 is —Z B R 5 , wherein each Z B is independently a bond or an optionally substituted aliphatic wherein up to four carbon units of Z B are optionally and independently replaced by —C(O)—, —C(S)—, —C(O)NR B —, —C(O)NR B NR B —, —C(O)O—, —C(O)C(O)—NR B —, —NR B C(O)O—, —NR B C(O)NR B —, —NR B NR B —, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, or —NR B SO 2 NR B —, provided that —SO—, —SO 2 —, or —SO 2 NR B — is not directly bound to the carbonyl in formula (I);
each R 5 is independently R B , halo, —OH, —CN, —NO 2 , —NH 2 , alkoxy, or haloalkoxy;
each R B is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
or, R 1 and R 2 , together with the atoms to which they are attached, form an optionally substituted heterocycloaliphatic ring;
each R 3 is an optionally substituted aliphatic, amino, sulfonyl, sulfanyl, sulfinyl, sulfonamide, sulfamide, sulfo, —O—R 3A , an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
each R 3A is independently an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl; and
each of Y and Y′ is H.
4. The method according to claim 3 , further comprising administering to said patient an agent selected from an immunomodulatory agent, an antiviral agent, an inhibitor of HCV protease, and an inhibitor of the HCV life cycle.
5. The method according to claim 4 , wherein said immunomodulatory agent is α-, β-, or γ-interferon or thymosin; said antiviral agent is ribavarin or amantadine; and said inhibitor of the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
6. A method of eliminating or reducing HCV contamination of a biological sample or medical or laboratory equipment, comprising the step of contacting said biological sample or medical or laboratory equipment with a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
each A is —CH 2 —;
each B is —CH 2 —;
each R 1 is
wherein:
U is a bond or —O—;
V is an alkyl;
T is —C(O)—; and
R is an aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, heteroaryl, alkoxy, or cycloalkoxy, and is optionally substituted with 1 to 3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, aliphatic, haloaliphatic, (aliphatic)oxy, (halo(aliphatic))oxy, (aliphatic(oxy(aryl)))oxy, aryl, heteroaryl, haloaryl, cycloaliphatic, or heterocycloaliphatic;
each R 2 is —Z B R 5 , wherein each Z B is independently a bond or an optionally substituted aliphatic wherein up to four carbon units of Z B are optionally and independently replaced by —C(O)—, —C(S)—, —C(O)NR B —, —C(O)NR B NR B —, —C(O)O—, —C(O)C(O)—NR B —, —NR B C(O)O—, —NR B C(O)NR b —, —NR B NR B —, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, or —NR B SO 2 NR B —, provided that —SO—, —SO 2 —, or —SO 2 NR B — is not directly bound to the carbonyl in formula (I);
each R 5 is independently R B , halo, —OH, —CN, —NO 2 , —NH 2 , alkoxy, or haloalkoxy;
each R B is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
or, R 1 and R 2 , together with the atoms to which they are attached, form an optionally substituted heterocycloaliphatic ring;
each R 3 is an optionally substituted aliphatic, amino, sulfonyl, sulfanyl, sulfonyl, sulfonamide, sulfamide, sulfo, —O—R 3A , an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
each R 3A is independently an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl; and
each of Y and Y′ is H.
7. The method according to claim 3 , further comprising administering to said patient an interferon having anti-hepatitis C virus activity.
8. The method of claim 7 , further comprising administering a compound having anti-hepatitis C virus activity, wherein said compound is other than an interferon.
9. The method of claim 8 , wherein said compound of the formula (I), said interferon, and said compound having anti-hepatitis C virus activity are each present in an amount selected from the group consisting of a pharmaceutically effective amount, a subclinical pharmaceutically effective amount, and a combination thereof.
10. The method of claim 9 , wherein said interferon is selected from the group consisting of: interferon alpha 2b, pegylated interferon alpha, consensus interferon, interferon alpha 2a, lymphoblastoid interferon, and interferon tau; and said compound having anti-hepatitis C virus activity is selected from the group consisting of thymosin, interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, double stranded RNA, double stranded RNA complexed with tobramycin, Imiquimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and telbivudine.
11. The method according to claim 3 , further comprising administering to said patient a pharmaceutically effective amount of a compound having anti-hepatitis C virus activity, wherein said compound is other than an interferon.
12. The method according to claim 3 , further comprising administering to said patient a pharmaceutically effective amount of a combination of:
a) pegylated interferon alpha; and
b) ribavirin.
13. The method according to claim 3 , wherein said compound of formula (I) is selected from the group consisting of:
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
and,
1005.
14. The method according to claim 13 , further comprising administering to said patient an agent selected from an immunomodulatory agent, an antiviral agent, an inhibitor of HCV protease, and an inhibitor of the HCV life cycle.
15. The method according to claim 14 , wherein said immunomodulatory agent is α-, β-, or γ-interferon or thymosin; said antiviral agent is ribavarin or amantadine; and said inhibitor of the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
16. The method according to claim 13 , further comprising administering to said patient a pharmaceutically effective amount of an interferon having anti-hepatitis C virus activity.
17. The method according to claim 16 , further comprising a compound having anti-hepatitis C virus activity, wherein said compound is other than an interferon.
18. The method of claim 17 , wherein said compound of the formula (I), said interferon, and said compound having anti-hepatitis C virus activity are each present in an amount selected from the group consisting of a pharmaceutically effective amount, a subclinical pharmaceutically effective amount, and a combination thereof.
19. The method of claim 18 , wherein said interferon is selected from the group consisting of: interferon alpha 2b, pegylated interferon alpha, consensus interferon, interferon alpha 2a, lymphoblastoid interferon, and interferon tau; and said compound having anti-hepatitis C virus activity is selected from the group consisting of thymosin, interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, double stranded RNA, double stranded RNA complexed with tobramycin, Imiquimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and telbivudine.
20. The method according to claim 13 , further comprising administering to said patient a pharmaceutically effective amount of a compound having anti-hepatitis C virus activity, wherein said compound is other than an interferon.
21. The method according to claim 13 , further comprising administering to said patient:
a) a pegylated interferon alpha; and
b) ribavirin.
22. The method according to claim 21 , wherein said compound of the formula (I), said pegylated interferon alpha, and said ribavirin are each present in an amount selected from the group consisting of a pharmaceutically effective amount, a subclinical pharmaceutically effective amount, and a combination thereof.
23. The method according to claim 1 , wherein said compound of formula (I) is selected from the group consisting of:
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
and,
1005.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.